Dr.Evidence Unveils Major Enhancements to AI-enabled Landscape Intelligence Platform for Life Sciences
September 12 2024 - 11:30AM
Business Wire
Helping Clients Accelerate Time-to-market while
Minimizing Risk by Streamlining Process, Increasing Transparency
and Enhancing Collaboration
Dr.Evidence, the preeminent AI-enabled landscape intelligence
platform helping life sciences enterprises get their products to
market and keep them there, today announced significant
enhancements to further accelerate clients’ time-to-market for new
drugs and indications and de-risk the possibility of missing
critical precedent from the market to support a successful path to
approval.
The Dr.Evidence platform incorporates the broadest global
content set available to generate landscape intelligence – over 100
million documents including pharmaceutical labels, regulatory
approval packages, clinical trials, published literature,
congresses and more. With specialized workflows, and advanced
sharing and monitoring capabilities, this gives teams the necessary
360-degree view of the landscape to effectively inform clinical
development and regulatory submission strategy.
The upgraded platform now features:
- Expanded Regulatory Intelligence module
incorporating FDA Guidance documents and Orange and Purple Book
content - Generative AI Chat capability for regulatory approval
packages - Literature Search module with Generative AI-powered
summarization Label Intelligence module covering 8 major health
authorities
Dr.Evidence will showcase these new capabilities at the RAPS
Convergence Conference in Long Beach, September 17-19.
Rose Higgins, CEO of Dr.Evidence, commented, “With two decades
of delivering fit-for-purpose technology solutions to the industry,
Dr.Evidence has acquired unsurpassed domain expertise and leverages
an 'augmented intelligence' approach to development, combining
‘human-in-the-loop’ and advanced AI capabilities to deliver
accurate and precise results, leading clients to an accelerated and
more confident path to market.”
The Dr.Evidence platform serves as the central source of truth
for pharmaceutical and biotechnology companies of all sizes,
increasing transparency, breaking down silos across departments and
geographies, and enhancing collaboration to more rapidly align on
strategic decisions and generate deliverables to advance products
into market, such as global regulatory strategy documents, briefing
books, meeting packages for health authorities, target product
profiles, company core data sheets, and long-range plans.
For organizations with generics and biosimilars on the market,
the Dr.Evidence platform delivers proactive monitoring and
notification of changes in innovator drug labels, as well as Orange
and Purple Book content, to support strategy and compliance.
For more information, visit Dr.Evidence at Booth #843 during the
RAPS Convergence Conference.
About Dr.Evidence
Dr.Evidence is the preeminent AI-enabled landscape intelligence
platform for life sciences, helping clients get their products to
market and keep them there. With 20 years of delivering
fit-for-purpose technology solutions to the industry, Dr.Evidence
has acquired unsurpassed domain expertise. The platform offers the
most expansive content set available -- pharmaceutical labels,
regulatory approval packages, health authority guidance documents,
clinical trials, published literature, congresses and more -- to
identify and analyze prior precedent and competitive products in
informing strategy. By driving dramatic efficiencies, transparency,
and collaboration across departments and geographies with
specialized workflows, Dr.Evidence helps clients generate the
critical deliverables needed to accelerate time-to-market.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912356493/en/
Cathy Finley +1 (310) 595-1265 pr@drevidence.com
https://www.drevidence.com/